Pediatr. praxi. 2026;27(3):142-147 | DOI: 10.36290/ped.2026.023

Eosinophilic esophagitis

MUDr. Nabil El-Lababidi
Klinika pediatrie a dědičných poruch metabolismu 1. LF UK a VFN v Praze

Eosinophilic oesophagitis (EoE) is a chronic, progressive, immunologically mediated disease of the oesophagus, which may cause symptoms of oesophageal dysfunction. Both the incidence and prevalence of EoE are increasing. Clinical presentations are varied and often non-specific. Traditionally associated symptoms with EoE, mainly dysphagia and food impaction, are present in school-aged children and adolescents. EoE treatment is based on elimination diet, proton pump inhibitors and/or topical corticosteroids. Anti-interleukin 4/13, dupilumab, may be considered as an option in refractory EoE cases. Prognosis of this disease is unknown.

Keywords: eosinophilic oesophagitis, food impaction, oesophagogastroduodenoscopy, mucosal eosinophilia, elimination diet, proton pump inhibitors, topical steroids, anti-interleukin 4/13, dupilumab.

Accepted: June 22, 2026; Published: July 1, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
El-Lababidi N. Eosinophilic esophagitis. Pediatr. praxi. 2026;27(3):142-147. doi: 10.36290/ped.2026.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 1.7.2027

    References

    1. El-Lababidi N. Dětská gastroenterologie, hepatologie a výživa pro klinickou praxi. Praha: Grada Publishing, a.s.; 2025.
    2. Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394-437. Go to original source... Go to PubMed...
    3. Papadopoulou A, Koletzko S, Heuschkel R, et al. Management Guidelines of Eosinophilic Esophagitis in Childhood. J Pediatr Gastroenterol Nutr. 2014;58(1):107-118. Go to original source...
    4. de Rooij WE, Barendsen ME, Warner MJ, et al. Emerging incidence trends of eosinophilic esophagitis over 25 years: Results of a nationwide register-based pathology cohort. Neurogastroenterol Motil. 2021;33(7):e14072. Go to original source... Go to PubMed...
    5. Mehta P, Furuta GT. Eosinophils in Gastrointestinal disorders - eosinophilic gastrointestinal diseases, celiac disease, inflammatory bowel disease and parasitic infections. Immunol Allergy Clin North Am. 2015; 35(3):413-437. Go to original source...
    6. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3): 335-358. Go to original source...
    7. Aceves SS, Dellon ES, Greenhawt M, et al. Clinical guidance for the use of dupilumab in eosinophilic esophagitis: A yardstick. Ann Allergy Asthma Immunol. 2023;130(3):371-378. Go to original source...
    8. Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239-2251. Go to original source... Go to PubMed...
    9. Moawad FJ. Eosinophilic Esophagitis: Incidence and Prevalence. Gastrointest Endosc Clin N Am. 2018;28(1):15-25. Go to original source...
    10. Carr S, Chan ES, Watson W. Eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):58. Go to original source...
    11. Attwood S, Epstein J. Eosinophilic oesophagitis: recent advances and practical management. Frontline Gastroenterol2021;12(7):644-649. Go to original source... Go to PubMed...
    12. Dellon ES, Hirano I. Epidemiology and Natural History of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):319-332.e3. Go to original source... Go to PubMed...
    13. Licari A, Votto M, D'Auria E, et al. Eosinophilic Gastrointestinal Diseases in Children: A Practical Review. Curr Pediatr Rev. 2020;16(2):106-114. Go to original source...
    14. Alexander ES, Martin LJ, Collins MH, et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol. 2014;134(5):1084-1092.e1. Go to original source...
    15. Rothenberg ME, Serpegel JM, Sherrill JD, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Gen. 2010;42(4):289-91. Go to original source... Go to PubMed...
    16. Kottyan LC, Davis BP, Sherrill JD, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014;46(8):895-900. Go to original source... Go to PubMed...
    17. Kottyan LC, Rothenberg ME. Genetics of eosinophilic esophagitis. Mucosal Immunol. 2017;109(3):580-588. Go to original source... Go to PubMed...
    18. Khokhar D, Marella S, Idelman G, et al. Eosinophilic esophagitis: Immune mechanisms and therapeutic targets. Clin Exp Allergy. 2022;52(10):1142-1156. Go to original source...
    19. Arias Á, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13(2):99-117. Go to original source...
    20. Jensen ET, Kappelman MD, Kim HP, et al. Early life exposures as risk factors for pediatric eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2013;57(1):67-71. Go to original source...
    21. Jensen ET, Dellon ES. Environmental factors and eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142(1):32-40. Go to original source... Go to PubMed...
    22. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489-495. Go to original source... Go to PubMed...
    23. Kagalwalla AF, Wechsler JB, Amsden K, et al. Efficacy of a 4-food elimination diet for children with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(11):1698-1707.e7. Go to original source...
    24. Molina-Infante J, Arias A, Barrio J, et al. A Four-food group elimination diet for adult eosinophilic esophagitis: a prospective multicenter study. J Allergy Clin Immunol. 2018;141(4): 1365-1372. Go to original source... Go to PubMed...
    25. Kurszewski PG, Russo JM, Franciosi JP, et al. Prospective, comparative effectiveness trial of cow's milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis: pediatric eosinophilic esophagitis therapy. Dis Esophagus. 2016;29(4):377-384. Go to original source...
    26. Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histological remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13-22.e1. Go to original source...
    27. Dellon ES, Muir AB, Katzka DA, et al. ACD Clinical Guideline: Diagnosis and Management of Eosinphilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59. Go to original source...
    28. Syverson EP, Rubinstein E, Lee JJ, et al. The role of dupilumab in the treatment of eosinophilic esophagitis. Immunotherapy. 2024;16(13):845-852. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.